Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 5/20 | 0.34 |
| ▸ | MERTK | Q12866 | 5/20 | 0.34 |
| ▸ | AXL | P30530 | 4/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24087299 | 0.79 | PDE4A (0.41) | PDE4APDE3ACYP3A4HPGDNFKB1 | |
| SCHEMBL30446178 | 0.79 | PDE4A (0.41) | PDE4APDE3ACYP3A4HPGDNFKB1 | |
| SCHEMBL21646478 | 0.79 | PDE4A (0.41) | PDE4APDE3ACYP3A4HPGDNFKB1 | |
| SCHEMBL11985799 | 0.77 | L3MBTL1 (0.44) | PDE4APDE3ACYP3A4HPGDNFKB1 | |
| SCHEMBL407441 | 0.77 | L3MBTL1 (0.49) | PDE4APDE3ACYP3A4HPGDNFKB1 | |
| SCHEMBL338573 | 0.76 | PDE4A (0.41) | PDE4APDE3ACYP3A4HPGDNFKB1 | |
| SCHEMBL25124615 | 0.75 | PDE4A (0.39) | PDE4APDE3ACYP3A4HPGDNFKB1 | |
| Hydrochloric Acid SCHEMBL31647268 | 0.75 | L3MBTL1 (0.47) | PDE4APDE3ACYP3A4HPGDNFKB1 | |
| SCHEMBL10514600 | 0.74 | PDE3A (0.70) | PDE4APDE3ACYP3A4HPGDNFKB1 | |
| SCHEMBL10515680 | 0.74 | PDE3A (0.54) | PDE4APDE3ACYP3A4HPGDNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112867715-B | 5-azaindazole derivatives as adenosine receptor antagonists | 默克专利股份公司 | 2024-03-05 | — | — | CN | disclosed |
| EP-3870582-B1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2023-07-19 | — | — | EP | disclosed |
| EP-3870582-B1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2023-07-19 | — | — | EP | disclosed |
| US-20210380606-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2021-12-09 | — | — | US | disclosed |
| US-20210380606-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2021-12-09 | — | — | US | disclosed |
| EP-3828174-A1 | PYRIDAZINONE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-06-02 | — | — | EP | disclosed |
| US-7951825-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951825-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100168159-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168159-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-7678820-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2010-03-16 | — | — | US | disclosed |
| US-7678820-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2010-03-16 | — | — | US | disclosed |
| US-20090076070-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090076070-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168159-A1 | HETERO COMPOUND | S1PR1, ENPP2, LPAR1 | PDE4A 3449/4885PDE3A 3516/4885CYP3A4 2863/4885 |
| US-20210380606-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA1 | PDE4A 67/4885PDE3A 112/4885CYP3A4 762/4885 |
| US-20090076070-A1 | HETERO COMPOUND | S1PR1, ENPP2, LPAR1 | PDE4A 3449/4885PDE3A 3516/4885CYP3A4 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.